A randomized investigator-blind study evaluating the efficacy and safety of 0.005% trifarotene cream versus 0.05% VAA cream in the treatment of moderate facial acne

A randomized investigator-blind study evaluating the efficacy and safety of 0.005% trifarotene cream versus 0.05% VAA cream in the treatment of moderate facial acne.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210531008

Enrollment

Registered

2021-05-31

Start date

2021-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate acne vulgaris patients Trifarotene, acne vulgaris, fourth-generation retinoid

Interventions

0.005%Trifarotene,0.05% VAA cream

Experimental Drug,Active Comparator Drug

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Male or female, 18-50 years of age 2. Participants who have been diagnosed with moderate acne at baseline visit 3. Participants must willingly give informed consent.

Exclusion criteria

Exclusion criteria: 1. Participants who have acneiform eruption (e.g., chloracne, drug-induced acne) or other facial inflammatory skin conditions precluding the acne assessment 2. Participants who have any uncontrolled or severe diseases or any medical or surgical conditions, such as polycystic ovarian syndrome, may interfere with the interpretation or compliance with the protocol 3. Participants who expose to excessive ultraviolet radiation within one month before the baseline visit or plan to expose intense UV during this trial 4. Participants who are unwilling to refrain from use of prohibited medication including topical (such as topical benzoyl peroxide, azelaic acid, or topical antibiotics) and systemic (such as systemic antibiotics, oral antiandrogens, or oral isotretinoin) medications affecting acne conditions during this trial 5. A pregnant woman or nursing or unable to use non-hormonal birth control 6. Participants who have a history of study drug allergy

Design outcomes

Primary

Measure	Time frame
the percentage of subjects who achieve investigator global assessment (IGA) score of 0 and 1 and have at least a 2-grade improvement. baseline, week 1, 2, 4, 8, 12 IGA score,inflammatory acne counts baseline, week 1, 2, 4, 8, 12 inflammatory acne counts,non-inflammatory acne count baseline, week 1, 2, 4, 8, 12 non-inflammatory acne count	—

Secondary

Measure	Time frame
safety and skin tolerability week 1, 2, 4, 8, 12 safety and skin tolerability,patient satisfaction week 1, 2, 4, 8, 12 satisfaction score (0-10)	—

Countries

Thailand

Contacts

Public ContactChanat Kumtornrut

Faculty of Medicine, Chulalongkorn university

chanat_1@yahoo.com66814594965

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026